FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4233655894> ?p ?o ?g. }

• W4233655894 endingPage "4397" @default.
• W4233655894 startingPage "4392" @default.
• W4233655894 abstract "Purpose To determine the efficacy and safety of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia (AML). Patients and Methods A phase II, open-label, multicenter study was conducted with single-agent clofarabine in pediatric patients with refractory or relapsed AML. Clofarabine was administered intravenously over 2 hours at the pediatric maximum-tolerated dose (MTD) of 52 mg/m 2 daily for 5 consecutive days. Cycles were repeated every 2 to 6 weeks. Responses determined by an independent response review panel. Results The 42 patients treated on the study had a median age of 13 years (range, 2 to 22 years) and had received a median number of two (range, one to five) prior regimens. The response rate was 26% and included one complete response without platelet recovery and 10 partial responses. The median duration of response was 20 weeks (range, 2 to ≥ 156 weeks). Six of 28 patients who were refractory to the immediately preceding therapy achieved response. Thirteen patients (31%), including seven responders, proceeded to hematopoietic stem-cell transplantation (HSCT) after treatment with clofarabine and survived between 24 to ≥ 160 weeks. Five patients (12%) remain alive post-transplantation at ≥ 63, ≥ 71, ≥ 86, ≥ 114, and ≥ 130 weeks. The most common grade 3 or greater adverse events without regard to causality were febrile neutropenia, catheter-related infection, epistaxis, hypotension, nausea, and fever. Transient elevation of liver enzymes and hypokalemia occurred frequently. Five patients died within 30 days of clofarabine administration secondary to progressive disease, and another five died as a result of an adverse event. Conclusion Clofarabine is active in pediatric patients with multiply relapsed or refractory AML. Responses allowed several refractory patients to proceed to HSCT. The toxicity profile was expected in this patient population." @default.
• W4233655894 created "2022-05-12" @default.
• W4233655894 creator A5002520656 @default.
• W4233655894 creator A5004008487 @default.
• W4233655894 creator A5024964015 @default.
• W4233655894 creator A5028056789 @default.
• W4233655894 creator A5033167405 @default.
• W4233655894 creator A5034653175 @default.
• W4233655894 creator A5037038601 @default.
• W4233655894 creator A5044030725 @default.
• W4233655894 creator A5062979200 @default.
• W4233655894 creator A5065709368 @default.
• W4233655894 creator A5071378074 @default.
• W4233655894 creator A5075871834 @default.
• W4233655894 creator A5076457958 @default.
• W4233655894 creator A5078227101 @default.
• W4233655894 creator A5080739165 @default.
• W4233655894 creator A5082967648 @default.
• W4233655894 date "2009-09-10" @default.
• W4233655894 modified "2023-10-14" @default.
• W4233655894 title "Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia" @default.
• W4233655894 cites W1534965621 @default.
• W4233655894 cites W1919339218 @default.
• W4233655894 cites W1935154669 @default.
• W4233655894 cites W1964952394 @default.
• W4233655894 cites W2027846898 @default.
• W4233655894 cites W2034324505 @default.
• W4233655894 cites W2038227731 @default.
• W4233655894 cites W2040336044 @default.
• W4233655894 cites W2040489908 @default.
• W4233655894 cites W2049310237 @default.
• W4233655894 cites W2053903261 @default.
• W4233655894 cites W2055690659 @default.
• W4233655894 cites W2058120958 @default.
• W4233655894 cites W2083089310 @default.
• W4233655894 cites W2102776788 @default.
• W4233655894 cites W2110496778 @default.
• W4233655894 cites W2116171965 @default.
• W4233655894 cites W2131637500 @default.
• W4233655894 cites W2160881482 @default.
• W4233655894 cites W2163334163 @default.
• W4233655894 cites W2246273267 @default.
• W4233655894 cites W2320078260 @default.
• W4233655894 cites W2409426682 @default.
• W4233655894 cites W2499823072 @default.
• W4233655894 cites W2552006696 @default.
• W4233655894 cites W4247297474 @default.
• W4233655894 cites W4255119797 @default.
• W4233655894 cites W4293241248 @default.
• W4233655894 doi "https://doi.org/10.1200/jco.2008.18.8706" @default.
• W4233655894 hasPublicationYear "2009" @default.
• W4233655894 type Work @default.
• W4233655894 citedByCount "60" @default.
• W4233655894 countsByYear W42336558942012 @default.
• W4233655894 countsByYear W42336558942013 @default.
• W4233655894 countsByYear W42336558942014 @default.
• W4233655894 countsByYear W42336558942015 @default.
• W4233655894 countsByYear W42336558942016 @default.
• W4233655894 countsByYear W42336558942017 @default.
• W4233655894 countsByYear W42336558942018 @default.
• W4233655894 countsByYear W42336558942019 @default.
• W4233655894 countsByYear W42336558942020 @default.
• W4233655894 countsByYear W42336558942021 @default.
• W4233655894 countsByYear W42336558942022 @default.
• W4233655894 countsByYear W42336558942023 @default.
• W4233655894 crossrefType "journal-article" @default.
• W4233655894 hasAuthorship W4233655894A5002520656 @default.
• W4233655894 hasAuthorship W4233655894A5004008487 @default.
• W4233655894 hasAuthorship W4233655894A5024964015 @default.
• W4233655894 hasAuthorship W4233655894A5028056789 @default.
• W4233655894 hasAuthorship W4233655894A5033167405 @default.
• W4233655894 hasAuthorship W4233655894A5034653175 @default.
• W4233655894 hasAuthorship W4233655894A5037038601 @default.
• W4233655894 hasAuthorship W4233655894A5044030725 @default.
• W4233655894 hasAuthorship W4233655894A5062979200 @default.
• W4233655894 hasAuthorship W4233655894A5065709368 @default.
• W4233655894 hasAuthorship W4233655894A5071378074 @default.
• W4233655894 hasAuthorship W4233655894A5075871834 @default.
• W4233655894 hasAuthorship W4233655894A5076457958 @default.
• W4233655894 hasAuthorship W4233655894A5078227101 @default.
• W4233655894 hasAuthorship W4233655894A5080739165 @default.
• W4233655894 hasAuthorship W4233655894A5082967648 @default.
• W4233655894 hasBestOaLocation W42336558941 @default.
• W4233655894 hasConcept C121332964 @default.
• W4233655894 hasConcept C126322002 @default.
• W4233655894 hasConcept C141071460 @default.
• W4233655894 hasConcept C142424586 @default.
• W4233655894 hasConcept C197934379 @default.
• W4233655894 hasConcept C2776694085 @default.
• W4233655894 hasConcept C2776863199 @default.
• W4233655894 hasConcept C2777063308 @default.
• W4233655894 hasConcept C2777198975 @default.
• W4233655894 hasConcept C2777408962 @default.
• W4233655894 hasConcept C2778041864 @default.
• W4233655894 hasConcept C2778461978 @default.
• W4233655894 hasConcept C2778729363 @default.
• W4233655894 hasConcept C2780580376 @default.
• W4233655894 hasConcept C2911091166 @default.

• next